Cephalon

Source: Wikipedia, the free encyclopedia.
For information about the head portion in arthropod anatomy, see Cephalon (arthropod head).

Cephalon, Inc.
Company type
Teva Pharmaceutical Industries
IndustryBiotechnology, Biopharmaceutical
Founded1987; 37 years ago (1987)
Founder
Headquarters
Gabitril[1]
Number of employees
3,726 (December 31, 2010)[citation needed]
Websitewww.cephalon.com

Cephalon, Inc. was an American

DuPont Company.[not verified in body] Baldino served as Cephalon's chairman and chief executive officer,[not verified in body] until his death in December 2010.[1] The company's name comes from the adjective "cephalic" meaning "related to the head or brain", as it was established primarily to pursue treatments for neurodegenerative diseases.[not verified in body
]

As noted by fundinguniverse.com, in its early years,

"Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms."[2]

Cephalon was first included in the Fortune 1000 list of U.S. companies based upon annual revenues for 2006.[not verified in body] Sales revenues reached $2.8 billion in 2010,[not verified in body] ranking Cephalon among the leading biopharmaceutical companies in the world at that time.[not verified in body]

On May 2, 2011,

Teva Pharmaceutical Industries announced it would acquire Cephalon.[3] The deal was completed on October 11, 2011.[4]

Product development and acquisition history

The company's early research efforts were focused on the development of

amyotrophic lateral sclerosis (Lou Gehrig's Disease), a candidate that was never approved.[citation needed
]

Thereafter, the company developed and commercialized products for the treatment of sleep disorders, pain,

Provigil, for the treatment of excessive daytime sleepiness associated with narcolepsy, sleep apnea, and shift work sleep disorder.[citation needed] Sales of Provigil reached nearly one billion dollars in 2008.[citation needed
]

In February 2009, Cephalon acquired the Australian biotechnology firm, Arana Therapeutics, which brought Cephalon its lead biologic candidate, ART621, a candidate for inflammatory diseases,[

better source needed
]

At the time of Baldino's death in 2010, the company he had co-founded in 1987 was best known for the alertness drug

Omapro, a therapeutic agent for a drug-resistant leukemia, in the oncology therapeutic area.[6]

Management and locations

Longtime chief financial officer J. Kevin Buchi succeeded Baldino as CEO in 2011.[7][8] Members of the board included:[when?] venture capitalist William Egan, former COR Therapeutics CEO Vaughan Kailian, prominent healthcare economist Dr. Gail Wilensky, former SmithKline Beecham executive Dr. Martyn Greenacre, former Harvard physician and Glaxo USA head Dr. Charles Sanders and former Ambassador Kevin Moley.[citation needed]

The company was headquartered west of

Salt Lake City, Utah.[citation needed] European operations were based near Paris, France.[citation needed] After the acquisition of Arana,[when?] Research and Development operations continued in Sydney, Australia.[citation needed
]

Legal issues

In 1999 Cephalon settled a lawsuit for $17 million in which it had faced claims that Baldino and other company executives had overstated the potential for a drug aimed at treating

better source needed
]

Products

Select products that Cephalon manufactured and marketed included:[when?][citation needed]

References

  1. ^ a b c d e f g Meier, Barry (December 21, 2010). "Frank Baldino Jr., Founder of Pharmaceutical Company, Dies at 57". The New York Times. Retrieved November 21, 2018.
  2. ^ Funding Universe Staff (November 30, 2015). "History of Cephalon, Inc". FundingUniverse.com. Retrieved November 30, 2015. As a small research house, Cephalon initially avoided involving itself in activities that would require maintaining a sales staff, managing clinical trials, and shepherding new drugs through the Food and Drug Administration (FDA) approval process. With no product to sell, Cephalon's only asset was its scientific expertise. That expertise proved sufficient to attract investors, and the company managed to fund its operations through research grants and contracts with larger pharmaceutical firms.
  3. better source needed
    ]
  4. better source needed
    ]
  5. ^ a b Staff Writer (February 24, 2010). "Cephalon To Acquire Ception Therapeutics". Archived from the original on July 13, 2011. Retrieved February 10, 2020.
  6. ^ Bennett, Simeon (March 29, 2011), "Cephalon agrees to acquire ChemGenex: Potential leukemia drug key to $230M purchase", Delaware Online, Bloomberg News, retrieved March 30, 2011
  7. ^ Writer, By Christopher K. Hepp, Inquirer Staff (December 23, 2010). "Cephalon names J. Kevin Buchi new CEO". inquirer.com. Retrieved September 10, 2020.{{cite web}}: CS1 maint: multiple names: authors list (link)
  8. ISSN 0099-9660
    . Retrieved September 10, 2020.
  9. ^ "Westlaw Sign In | Thomson Reuters". signon.thomsonreuters.com. Retrieved February 21, 2020.
  10. better source needed
    ]

External links

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cephalon&oldid=1214476607"